230 related articles for article (PubMed ID: 27914740)
1. Predicting the relative impacts of maternal and neonatal respiratory syncytial virus (RSV) vaccine target product profiles: A consensus modelling approach.
Pan-Ngum W; Kinyanjui T; Kiti M; Taylor S; Toussaint JF; Saralamba S; Van Effelterre T; Nokes DJ; White LJ
Vaccine; 2017 Jan; 35(2):403-409. PubMed ID: 27914740
[TBL] [Abstract][Full Text] [Related]
2. Vaccine Induced Herd Immunity for Control of Respiratory Syncytial Virus Disease in a Low-Income Country Setting.
Kinyanjui TM; House TA; Kiti MC; Cane PA; Nokes DJ; Medley GF
PLoS One; 2015; 10(9):e0138018. PubMed ID: 26390032
[TBL] [Abstract][Full Text] [Related]
3. RSV vaccine use--the missing data.
Drysdale SB; Sande CJ; Green CA; Pollard AJ
Expert Rev Vaccines; 2016; 15(2):149-52. PubMed ID: 26636902
[TBL] [Abstract][Full Text] [Related]
4. Respiratory syncytial virus infections in India: Epidemiology and need for vaccine.
Broor S; Parveen S; Maheshwari M
Indian J Med Microbiol; 2018; 36(4):458-464. PubMed ID: 30880691
[TBL] [Abstract][Full Text] [Related]
5. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development.
Graham BS
Immunol Rev; 2011 Jan; 239(1):149-66. PubMed ID: 21198670
[TBL] [Abstract][Full Text] [Related]
6. Potential impact of maternal vaccination on life-threatening respiratory syncytial virus infection during infancy.
Scheltema NM; Kavelaars XM; Thorburn K; Hennus MP; van Woensel JB; van der Ent CK; Borghans JAM; Bont LJ; Drylewicz J
Vaccine; 2018 Jul; 36(31):4693-4700. PubMed ID: 29941327
[TBL] [Abstract][Full Text] [Related]
7. Defining the vaccination window for respiratory syncytial virus (RSV) using age-seroprevalence data for children in Kilifi, Kenya.
Nyiro JU; Kombe IK; Sande CJ; Kipkoech J; Kiyuka PK; Onyango CO; Munywoki PK; Kinyanjui TM; Nokes DJ
PLoS One; 2017; 12(5):e0177803. PubMed ID: 28531224
[TBL] [Abstract][Full Text] [Related]
8. Potential impact of a maternal vaccine for RSV: A mathematical modelling study.
Hogan AB; Campbell PT; Blyth CC; Lim FJ; Fathima P; Davis S; Moore HC; Glass K
Vaccine; 2017 Oct; 35(45):6172-6179. PubMed ID: 28967522
[TBL] [Abstract][Full Text] [Related]
9. Evaluating vaccination strategies for reducing infant respiratory syncytial virus infection in low-income settings.
Poletti P; Merler S; Ajelli M; Manfredi P; Munywoki PK; Nokes D; Melegaro A
BMC Med; 2015 Mar; 13():49. PubMed ID: 25857701
[TBL] [Abstract][Full Text] [Related]
10. Maternal immunization with respiratory syncytial virus fusion protein formulated with a novel combination adjuvant provides protection from RSV in newborn lambs.
Garg R; Latimer L; Wang Y; Simko E; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
Vaccine; 2016 Jan; 34(2):261-269. PubMed ID: 26616551
[TBL] [Abstract][Full Text] [Related]
11.
van Erp EA; van Kasteren PB; Guichelaar T; Ahout IML; de Haan CAM; Luytjes W; Ferwerda G; Wicht O
J Virol; 2017 Nov; 91(21):. PubMed ID: 28794038
[TBL] [Abstract][Full Text] [Related]
12. Mathematical modelling of respiratory syncytial virus (RSV) in low- and middle-income countries: A systematic review.
Mezei A; Cohen J; Renwick MJ; Atwell J; Portnoy A
Epidemics; 2021 Jun; 35():100444. PubMed ID: 33662812
[TBL] [Abstract][Full Text] [Related]
13. Modelling the impact of respiratory syncytial virus (RSV) vaccine and immunoprophylaxis strategies in New Zealand.
Prasad N; Read JM; Jewell C; Waite B; Trenholme AA; Huang QS; Grant CC; Newbern EC; Hogan AB
Vaccine; 2021 Jul; 39(31):4383-4390. PubMed ID: 34147296
[TBL] [Abstract][Full Text] [Related]
14. Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy?
Munoz FM
Curr Opin Infect Dis; 2015 Jun; 28(3):221-4. PubMed ID: 25918956
[TBL] [Abstract][Full Text] [Related]
15. Passive and active immunization against respiratory syncytial virus for the young and old.
Villafana T; Falloon J; Griffin MP; Zhu Q; Esser MT
Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28525961
[TBL] [Abstract][Full Text] [Related]
16. Modelling the household-level impact of a maternal respiratory syncytial virus (RSV) vaccine in a high-income setting.
Campbell PT; Geard N; Hogan AB
BMC Med; 2020 Nov; 18(1):319. PubMed ID: 33176774
[TBL] [Abstract][Full Text] [Related]
17. Impact and cost-effectiveness of strategies to prevent respiratory syncytial virus (RSV) disease in Vietnam: A modelling study.
Do LAH; Le NTN; Mahmud S; Mulholland K; Pecenka C; Clark A
Vaccine; 2023 Nov; 41(46):6782-6790. PubMed ID: 37690873
[TBL] [Abstract][Full Text] [Related]
18. Vaccination against respiratory syncytial virus in pregnancy: a suitable tool to combat global infant morbidity and mortality?
Saso A; Kampmann B
Lancet Infect Dis; 2016 Aug; 16(8):e153-63. PubMed ID: 27317449
[TBL] [Abstract][Full Text] [Related]
19. RSV--a substantial slice of the airway disease burden and the way to a vaccine.
Weigl JA
Paediatr Int Child Health; 2012 Nov; 32 Suppl 2():S9-15. PubMed ID: 23394753
[TBL] [Abstract][Full Text] [Related]
20. Respiratory syncytial virus infection and disease in infants and young children observed from birth in Kilifi District, Kenya.
Nokes DJ; Okiro EA; Ngama M; Ochola R; White LJ; Scott PD; English M; Cane PA; Medley GF
Clin Infect Dis; 2008 Jan; 46(1):50-7. PubMed ID: 18171213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
